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Abstract
Background:  Alpha-fetoprotein (AFP) expression can resume in the adult liver under
pathophysiological conditions. Orphan nuclear receptors were supposed to regulate AFP gene
expression, in vitro. We were interested to study the expression of AFP and orphan nuclear
receptors, in vivo.
Results: The expression of AFP gene and orphan nuclear receptors in the liver was examined in
different rat models: (a) fetal liver (b) liver regeneration [partial hepatectomy (PH) with and without
2-acetyl-aminofluren treatment (2-AAF)], (c) acute liver damage [treatment with CCl4] and (d)
acute phase reaction [treatment with turpentine oil]. After PH of 2-AAF treated rats, clusters of
AFP positive cells occurred in the periportal region. In the Northern blot analysis, a positive
hybridization signal for the full-length AFP-RNA was observed only in liver samples from 2-AAF
treated rats after PH. In real-time PCR analysis, the full-length AFP-RNA was highly up regulated in
the fetal liver (maximum at day 14: 21,500 fold); after PH of 2-AAF treated rats, the full-length AFP-
RNA was also up regulated up to 400 fold (day 7 after PH). The orphan nuclear receptors were
down regulated at nearly each time points in all models, also at time point of up regulation of the
AFP gene.
Conclusion: Expression of "fetal" AFP could be demonstrated during liver development and
during proliferation of the so-called oval cells. Changes of expression of orphan nuclear receptors,
however, did not correlate with AFP expression. Other regulatory pathways were possibly
involved in controlling AFP expression, in vivo.
Background
During severe and chronic liver damage, a subpopulation
of liver cells termed oval cells was induced to proliferate.
The oval cells are not typical hepatocytes; they are indeed
less mature cells that can function as progenitors for either
hepatocytic or ductal cell lineages. This kind of cells
express alpha-fetoprotein (AFP) transcripts [1-3]. AFP is
an oncofetal gene, which occurs at high rate in the yolk
sac, fetal liver and intestine; but is otherwise shut off in the
first weeks after birth [4,5]. In the adult liver, AFP is
expressed in only very small amounts; nonetheless, AFP
expression can resume in certain pathophysiological situ-
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ations, such as liver regeneration (e.g., after surgical resec-
tion) and liver carcinogenesis (e.g., hepatocellular
carcinoma). Increased AFP gene expression occurs, for
example, in humans suffering from chronic liver disease
[6-9] and was considered to be a marker for hepatocellular
carcinoma [8,10]. For studying the expression of AFP, in
vivo, different animal models of liver damage, regenera-
tion and carcinogenesis are available. In the rat liver mul-
tiple AFP-RNA transcripts can be generated. The different
AFP-RNA transcripts are differentially regulated during
development, the full-length AFP-RNA [major form; 2.1
kilobases (kb)] is highly expressed in the fetal liver and
the three smaller variants (1.7, 1.4 and 1.0 kb) are
expressed in adult rat liver [11]. The full-length AFP-RNA,
however, is strongly increased in rat livers with prolifera-
tion of a putative progenitor cell compartment [11,12].
The smaller transcript sizes of the AFP-RNA are expressed
in adult rat liver and their steady state level does not
change significantly in regenerating livers after partial
hepatectomy (PH) or after toxic liver injury.
For understanding the mechanism of liver regeneration
and hepatocarcinogenesis, it might be important some
further knowledge about the regulation of the AFP gene.
The transcription of the AFP gene is under the control of,
at least, three enhancers and one silencing element in rat
and mouse [13-15]. These factors work in a highly tissue-
specific manner in the three organs derived from the
endodermal layer – namely, the yolk sac, liver and intes-
tine. In a carefully performed study, in vitro, and pub-
lished recently, Bois-Joyeux et al . suggested that amounts
and/or activities of the orphan nuclear receptors could
modulate AFP gene expression in different pathophysio-
logical conditions, such as liver regeneration and liver car-
cinogenesis [16]. Two closely related groups of
transcription factors seemed to be involved in the regula-
tion of AFP gene expression, explicitly the retinoic acid
receptor-related orphan receptor (ROR) and Rev-Erb
group. The first group contains three genes: ROR-α, ROR-
β and ROR-γ ; the second group includes Rev-Erb A and
Rev-Erb B. The ROR-α, Rev-Erb A and Rev-Erb B gene
products are co-expressed in several tissues, including the
heart, brain, liver and skeletal muscle [17-20]. The RORs
act mostly as activators, whereas the Rev-Erb gene prod-
ucts most often act as transcription repressors [18,21].
Both families of transcription factors act together with
cofactors, such as GRIP-1 for RORs [22] and N-CoR for
Rev-Erbs [23]. As both nuclear factors bind to regulatory
sites with very similar DNA sequences, there is a possibil-
ity of a cross-talk between different signalling pathways.
Furthermore, both ROR-α and Rev-Erb A modulate the
effect of other nuclear factors such as T3 receptor on tran-
scription level [24]. In vitro experiments suggested that the
AFP gene is a target of ROR-α, Rev-Erb A and Rev-Erb B.
Over-expression of ROR-α stimulated the activity of the
AFP enhancers in a dose-dependent manner whereas
overproduction of Rev-Erb A and Rev-Erb B had a down
regulating effect [16].
The aim of this study was to analyse the expression of full-
length AFP-RNA, as a possible oval cell marker, and the
expression of the orphan nuclear receptor (Rev-Erb A,
Rev-Erb B and N-CoR) during liver regeneration [PH with
or without 2-acetyl-aminofluren (2-AAF) treatment],
acute liver injury [CCl4 treatment] and in the fetal rat liver.
Therefore, we studied the distribution of the AFP-RNA
(full-length as well as smaller sizes of AFP-RNA) by real-
time PCR, by Northern blot and Western blot analyses, in
rat liver after CCl4 treatment, after PH with and without 2-
AAF treatment and in the fetal liver. Additionally, we stud-
ied AFP gene expression in the liver of rats after intramus-
cular injection of turpentine oil (model of acute phase
response), as a control. At the same time points the
expression of Rev-Erb A, Rev-Erb B and N-CoR were stud-
ied on mRNA level by real-time PCR.
We found that orphan nuclear receptor genes were not
only down regulated when the "fetal" AFP gene was up
regulated but also in cases where it was unchanged, ques-
tioning the regulatory role of those genes on expression of
fetal AFP, in vivo.
Results
Expression of AFP protein in the different rat models
Liver cryostat sections were performed from all used ani-
mal models (normal liver regeneration, liver regeneration
via oval cells, acute liver injury by CCl4-treatment and
acute phase response by turpentine oil treatment). Immu-
nostaining with an antibody against AFP showed that
AFP-positive cells could be seen only in the liver of 2-AAF
treated rats after PH. AFP-positive cells were localized in
clusters of oval cells, in the periportal region, at day 7 after
PH with 2-AAF treatment (Figure 1). No AFP-positive cells
could be seen during normal liver regeneration, after
acute liver injury or after injection of turpentine oil.
Expression of different AFP transcripts
In the past, it was published by different groups that dur-
ing liver regeneration by proliferation of putative progen-
itor cells (the so-called oval cells) the full-length AFP-RNA
is highly expressed. In rats treated with 2-AAF after PH, the
proliferation of the hepatocytes is blocked and the regen-
eration of the liver takes place by differentiation of the
oval cells into hepatocytes. By Northern blot analysis (Fig-
ure 2), we could be shown that the full-length APF-RNA is
expressed in this situation. For real-time PCR analysis two
different primers pairs (AFP1 and AFP2) (Table 1) were
designed. Real-time PCRs were performed at the same
time points with those primers, interestingly in the case of
primer AFP1 a strong increase of specific transcripts couldComparative Hepatology 2006, 5:2 http://www.comparative-hepatology.com/content/5/1/2
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be observed in comparison to the control and in case of
primer AFP2 only a weak increase could be observed. To
make sure that primer AFP1 can detect possibly the oval
cell specific full-length AFP-RNA during liver regeneration
in 2-AAF treated rats after PH, the amplification product
of primer AFP1 was used as a probe for Northern blot
analysis. The latter was performed with liver RNA samples
of 2-AAF treated rats after PH and after sham operation. A
positive hybridization signal, of about 2.1 kb, was
observed only in liver samples from 2-AAF treated rats
after PH; but not after sham operation (Figure 2). In order
to support our assumption, the two primer pairs were also
tested in fetal rat liver – here, the full-length AFP-RNA is
highly expressed. Real-time PCR analysis showed a strong
increased expression of full-length AFP-RNA (AFP1) with
a maximum at day 14 (21,500 fold) post coitum and only
a weak expression (582 fold) of the smaller AFP-RNA var-
iants (AFP2) at the same time points (Figure 6) could be
demonstrated. Therefore, we concluded that primer AFP1
detects the full-length AFP-RNA and the primer AFP2
detects the truncated AFP.
Real-time PCR analysis was performed with primer AFP1,
which detects the full-length AFP-RNA, and primer AFP2,
which detects the smaller splicing products. The expres-
sion of the AFP gene was examined in the liver of different
rat models: a) model of liver regeneration with prolifera-
tion of oval cells (PH in 2-AAF treated rats – sham opera-
tion in 2-AAF treated rats were used as appropriate
controls); b) model of normal liver regeneration (PH
without 2-AAF treatment – sham operation were used as
appropriate controls); c) model of acute liver injury (CCl4
treatment of rats); d) in a model of acute phase reaction
(turpentine oil treatment of rats); and e) fetal liver (Fig-
ures 3 to 7). Although the model of acute phase reaction
is not a model for liver regeneration, but because dramatic
changes of liver gene expression were observable, it was
used as a control. We performed two different series for
each model, and the mean values and the standard devia-
tion for the AFP gene expression were shown in the fig-
ures.
In 2-AAF treated rats, the expression of the full-length
AFP-RNA (AFP1) increased from day 1 (-0.2 fold) after PH
to the maximum at day 7 (399 fold) after PH. From day 7
to day 13, a decrease to 56.9 fold could be observed (Fig-
ure 3). The smaller splicing products of AFP (AFP2),
which are not specific for oval cells, were only slightly ele-
vated between day 3 and day 13 after PH (Figure 3). No
increase was observed in AAF-treated rats after sham oper-
ation (data not shown).
In rats undergoing PH (Figure 4) or in sham operation
without AAF-treatment (data not shown) no increase of
the full-length AFP-RNA (AFP1) was observed, the full-
length AFP-RNA is slightly down regulated at each time
point in comparison to the control. The smaller splicing
products (AFP2) showed a continuous down regulation
up to 16 hours with a maximum of -25.7 fold. Relating to
16 hours an increase of the smaller splicing products up to
-5.1 fold could be observed after 24 hours. Afterwards, the
level did not change up to 72 hours.
In rats treated with CCl4 a decrease of the full-length AFP-
RNA (AFP1; – 4.5 fold) and the smaller splicing products
(AFP2; -4.5 fold) could be seen after 12 hours. Then, a
continuous increase of both products with a maximum
after 72 hours (AFP1 up to 7.0 fold and AFP2 up to 4.8
fold) (Figure 5) could be observed.
Immunohistochemical detection of AFP in progenitor cells Figure 1
Immunohistochemical detection of AFP in progenitor cells. Immunohistochemical detection of AFP in progenitor cells 
(oval cells) in the rat liver. The right panel represents a higher magnification of the portal field admitted by black box.
PH AAF day 7 PH AAF day 7
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In the fetal rat liver, in comparison to a normal rat liver
control, a strong increase of the full-length AFP-RNA
(AFP1) could be detected with a maximum at day 14
(21,500 fold); subsequently, a decrease down to 1000
fold could be seen at day 18 (Figure 6). In the case of the
smaller variants of AFP-RNA (AFP2), a clear smaller
increase could be observed with also a maximum at day
14 (582 fold) (Figure 6).
In the control model of acute phase reaction, only slightly
changes of the full-length AFP-RNA (AFP1) and of the
smaller sizes of AFP-RNA (AFP2) could be observed (Fig-
ure 7).
Expression of Rev-Erb A, Rev-Erb B and N-CoR transcripts
The expression of the orphan nuclear receptors genes was
analysed by real-time PCR in rat models of liver regenera-
tion, acute liver injury, in the fetal liver and as control in
acute phase response. For each model, we performed two
different series and the mean values and standard devia-
tions were shown in the Figures 3 to 7
After PH in 2-AAF treated rats, the full-length AFP-RNA
(AFP1) was strongly increased at day 7 (399 fold) and at
day 11 (129.8 fold). The smaller sizes of AFP-RNA (AFP2)
were only increased at these time points to a small extent.
After PH a down regulation of Rev-Erb A occurs at day 1 (-
3.9 fold), day 3 (-5.5 fold), day 7 (-3.0 fold) and day 13 (-
12.7). The strongest up regulation of the full-length AFP-
RNA could be observed at day 7; four days later, Rev-Erb
A showed the strongest down regulation (-32.3 fold). Rev-
Erb B was slightly down regulated at each time point; the
strongest down regulation could be observed at day 13 (-
4.3 fold). N-CoR showed only slight changes in this
model (Figure 3).
After PH without 2-AAF treatment, a down regulation of
Rev-Erb A, Rev-Erb B and N-CoR could be detected at each
time point. The strongest down regulation of Rev-Erb A
and Rev-Erb B could be observed after 16 hours (Rev-Erb
A -21.5 fold and Rev-Erb B -25.7 fold). At the same time
point, also the strongest down regulation of both AFP-
RNA products (AFP1 and AFP2) could be detected (Figure
4).
In the case of acute liver damage after CCl4 treatment, a
continuous decrease of Rev-Erb A from 6 hours (-9.4 fold)
to the maximum at 48 hours (-102.3 fold) could be
observed; but after 24 hours in relation to the control no
changes could be detected. From 48 hours (-102.3 fold) to
96 hours (+2.1 fold) an up regulation of Rev-Erb A could
be seen. Rev-Erb B shows continuous down regulation
from 6 hours (-4.8 fold) to 72 hours (-22.1 fold), but after
24 hours in relation to the control no changes could be
detected. From 72 hours (-22.1 fold) to 96 hours (+2.0
fold) an up regulation of Rev-Erb B could be seen. N-CoR
shows only slight changes in this model (Figure 5).
In the fetal liver Rev-Erb A and Rev-Erb B are down regu-
lated at each time point, the maximum down regulation
was reached at day 12 (Rev-Erb A: 270 fold/Rev-Erb B: 186
fold), two days before the maximum up regulation of full-
length AFP RNA. N-CoR was slightly down regulated at
each time point (about 1.5 fold) (Figure 6).
In the rat model of acute phase reaction, the strongest
down regulation of Rev-Erb A occurs at 2 hours (-14.1
fold), 24 hours (-22.8 fold) and 36 hours (-23.4 fold)
after turpentine oil treatment. A continuous increase of
Rev-Erb B could be seen from 30 minutes (+1.7 fold) to 4
hours (+4.7 fold) after treatment with turpentine oil, with
exception of 2 hours; at this time point, Rev-Erb B was
down regulated. From 4 hours (+ 4.7 fold) to 24 hours (-
4.6 fold) a continuous down regulation of Rev-Erb B
Detection of the oval cell typical AFP-RNA product by  Northern blot analysis Figure 2
Detection of the oval cell typical AFP-RNA product 
by Northern blot analysis. Northern blot analysis was 
performed with liver RNA samples of 2-AAF treated rats 
after partial hepatectomy or after sham operation. The 
amplification product of the AFP1 primer pair was used as 
32P labelled probe. The first two lanes represent control 
samples of normal liver (Co) and 2-AAF fed animals (2-AAF-
Co). In the middle RNA samples of sham operations at day 3 
and day 7 are shown. The two lanes on the right site show 
RNA samples from day 3 and day 7 after partial hepatectomy 
of 2-AAF treated rats. In these samples, the oval cell typical 
product of 2.1 kb is detectable.Comparative Hepatology 2006, 5:2 http://www.comparative-hepatology.com/content/5/1/2
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could be detected; after that, Rev-Erb B was up regulated
again (48 hours: + 2.0 fold) (Figure 7).
Western blot analysis of Rev-Erb A and Rev-Erb B 
expression in the different rat models and 
immunhistological staining
The results of Rev-Erb A and Rev-Erb B expression should
be verified on protein level. Therefore, Western blot anal-
yses were performed with samples of PH rats with and
without 2-AAF treatment. Actually, only human specific
antibodies against Rev-Erb A and Rev-Erb B are available,
whereas Rev-Erb B should cross-react with the rat. Those
available antibodies have been not tested from the manu-
factures in "natural samples", they have only been tested
in CHO-cells transfected with full-length Rev-Erb A and
Rev-Erb B transcript. The protein size of the Rev-Erb A and
Rev-Erb B is 70 kDa. In the Western blot analysis, no spe-
cific band could be detected at 70 kDa (data not shown).
There are two possible reasons for our finding: (1) the
antibodies are not specific for rat samples or (2) the pro-
tein level is too low, because Rev-Erb A and Rev-Erb B are
down regulated in our models. Samples for Western blot
analysis were also extracted from rat hepatoblasts and
human hepatoma cells (Hep G2, Hep 3B); but also in
these cell-lines no specific band could be detected at 70
kDa.
The same antibodies were also used for immunohistolog-
ical techniques. Different immunohistological techniques
(standard indirect peroxidase staining and enhanced per-
oxidase-based detection (Envision; DAKO, Glostrup,
Denmark)) were applied on differently fixated liver sec-
tions (methanol-acetone fixated and paraformaldehyde
fixated) proved unsuccessful in the rat (data not shown).
Western blot analysis of AFP expression in the different 
models
The expression of the AFP protein was analysed by West-
ern blot technique. The full-length AFP-RNA, which is
highly expressed in the fetal liver, is translated into 68 kDa
and 70 kDa proteins, whereas the smaller AFP-RNA vari-
ants, which are expressed in the adult liver, are translated
into smaller proteins of 58 kDa, 54 kDa and 44 kDa [11].
Firstly, we performed Western blot analysis with fetal liver
(days 12, 14, 16 and 18) for verifying whether the used
AFP antibody detected the full-length AFP-RNA protein of
68 kDa and 70 kDa. In the Western blot analysis at day 14,
a strong band could be detected at 68 kDa and 70 kDa
(Figure 8).
Then, we performed Western blot analysis with samples of
rat livers after PH with and without 2-AAF treatment. In
the samples of rats treated with 2-AAF, only a weak band
could be detected at a protein size of 68 kDa and 70 kDa,
in comparison to the fetal liver with no changes at the dif-
ferent time points.
Discussion
AFP is a fetal glycoprotein produced by the yolk sac, fetal
liver and intestine, but its synthesis is shut off after birth
[25]. AFP is used as a serum marker for diagnosis of hepa-
tocellular carcinoma [8,26]. Elevated serum AFP level has
also been observed in various chronic liver diseases,
where continuous hepatocellular damage occurs and
hepatocellular regeneration is supposed to take place [27].
In this case, mature hepatocytes are supposed to differen-
tiate back to hepatoblasts and to be responsible for the
increased serum levels of fetal AFP. Nevertheless, and in
one study, AFP expression was not found in regenerating
human liver after PH [28]. Although many investigations
Table 1: Primer sequences and other PCR analysis related details.
Gene Primer Tm (°C) Number of cycles Product size (bp)
AFP1 5'-GCCCAGCATACGAAGAAAACA-3'
5'-TCTCTTTGTCTGGAAGCATTCCT-3'
60 40 179
AFP2 5'-ACTACTTACAAAATCTGTTCCTCATTGG-3'
5'-ATGTAAATGTCGGCCAGTCC-3'
60 40 169
Rev-Erb A 5'-CCATGTTTGACTTCAGCGAGAA-3'
5'-AAGTACCACTGCCGTGAAAAGG-3'
60 40 80
Rev-Erb B 5'-GAGCATGCCACCCCATAGAG-3'
5'-TATTGCTCCACATTCCTGGGA-3'
60 40 51
N-CoR 5'-TCTGCTTTGTCGTCCACACC-3'
5'-GCTGTAGCGACTTGACGGTTTA-3'
60 40 51
β-actin 5'-GAAATCGTGCGTGACATTAAAGAG-3'
5'-GCGGCAGTGGCCATCTC-3'
60 40 74Comparative Hepatology 2006, 5:2 http://www.comparative-hepatology.com/content/5/1/2
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on the function of AFP had been carried out, the regula-
tion and biological role of AFP is still unclear.
The adult liver can regenerate by mature hepatocytes
reentering into cell cycle after surgical resection or injury.
However, this proliferative response is often impaired in
chronic liver disease. Activation of a facultative stem cell
compartment (oval cells) is considered as an alternative
mechanism for regeneration in chronic liver disease [29-
31]. In rodent models of hepatocarcinogenesis and non-
carcinogenic injury models, it has been suggested that
oval cells might represent a facultative hepatic progenitor/
stem cell compartment proliferating and differentiating
both into hepatocytes and biliary epithelial cells, under
certain conditions [32-34]. PH combined with 2-AAF
feeding is a traditional model to activate oval cells, in rat
liver [35,36]. Several markers for oval cells have been sug-
gested. However, many of those markers are not specific
for oval cells; but are expressed by biliary epithelial cells
(CK-7, CK-19) and by hematopoietic cells (c-kit, Thy-1)
[37,38]. AFP gene expression seems to represent the most
reliable marker for oval cells, because it is widely studied
in human and animal models and it is not expressed by
Expression of AFP gene and Rev-Erb A, Rev-Erb B and N- CoR in liver regeneration without 2-AAF treatment Figure 4
Expression of AFP gene and Rev-Erb A, Rev-Erb B 
and N-CoR in liver regeneration without 2-AAF 
treatment. After partial hepatectomy without 2-AAF treat-
ment the expression of AFP gene (A) and of Rev-Erb A, Rev-
Erb B and N-CoR (B) were measured by real-time PCR, in 
the rat liver. The mean values and the standard deviations of 
two different series are demonstrated. From 2 up to 16 
hours, a down regulation of the smaller variants of AFP-RNA 
(AFP2) could be seen. Compared to 16 hours value an 
increase of the smaller splicing products up to -5.1 fold could 
be observed after 24 hours; afterwards, the level do not 
change up to 72 hours. The full-length AFP-RNA shows only 
slight changes. The genes of orphan nuclear receptors are 
down regulated at each time point. Rev-Erb A and Rev-Erb B 
are maximally down regulated after 16 hours similarly to the 
smaller variants of AFP-RNA (AFP2).
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Expression of AFP gene and Rev-Erb A, Rev-Erb B and N- CoR in liver regeneration with 2-AAF treatment Figure 3
Expression of AFP gene and Rev-Erb A, Rev-Erb B 
and N-CoR in liver regeneration with 2-AAF treat-
ment. After partial hepatectomy in 2-AAF treated rats, the 
expression of the AFP gene (A) and of Rev-Erb A, Rev-Erb B 
and N-CoR (B) were measured by real-time PCR. The mean 
values and the standard deviations of two different series are 
demonstrated. At day 7, the full-length AFP-RNA (AFP1) is 
maximally increased. The smaller variants of AFP-RNA 
(AFP2) showed no significant changes. Four days after the 
maximum increase of the full-length AFP-RNA Rev-Erb A is 
maximally decreased. Rev-Erb B is slightly decreased at each 
time point. N-CoR shows only slight changes in this model.
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other cell types, with the exception of some hepatocellular
carcimoma cells [11]. We studied the expression of the
full-length AFP-RNA (major form, 2.1 kb mRNA) and of
the smaller splicing variants during liver regeneration,
acute liver injury, in the fetal liver and under conditions of
acute phase response in the rat. Northern blot analysis
showed that the full-length AFP-RNA occurs only after PH
in 2-AAF treated rats; but not after sham operation of 2-
AAF treated rats or in normal controls.
Immunohistochemistry revealed clusters of AFP-positive
cells in the periportal region of 2-AAF treated rats after PH
at day 7, the typical area in which early proliferation of
oval cells takes place [39]. At the same time points, real-
time PCR analysis were performed with the two different
AFP primers (AFP1 and AFP2). Interestingly, and in the
case of primer AFP1, a strong increase could be observed
in comparison to the normal control and in case of primer
AFP2 only a weak increase could be observed. For verify-
ing whether primer AFP1 could possibly detect the full-
length AFP-RNA during liver regeneration in 2-AAF
treated rats after PH, the amplification product of primer
AFP1 was used as a probe for Northern blot analysis. This
Expression of AFP gene and Rev-Erb A, Rev-Erb B and N- CoR in fetal rat liver Figure 6
Expression of AFP gene and Rev-Erb A, Rev-Erb B 
and N-CoR in fetal rat liver. The expression of the AFP 
gene (A) and of Rev-Erb A, Rev-Erb B and N-CoR (B) were 
measured by real-time PCR in the fetal rat liver. The full-
length AFP-RNA reach the maximum at day 14 (21,500 fold); 
afterwards, a continuous decrease up to day 18 could be 
observed. Rev-Erb A and Rev-Erb B are down regulated at 
each time point, the maximum down regulation could be 
seen after 12 days. N-CoR was slightly down regulated at 
each time point (about 1.5 fold).
A
B
Expression of AFP gene and Rev-Erb A, Rev-Erb B and N- CoR in the rat model of acute liver damage Figure 5
Expression of AFP gene and Rev-Erb A, Rev-Erb B 
and N-CoR in the rat model of acute liver damage. 
After CCl4 treatment, the expression of the AFP gene (A) 
and of Rev-Erb A, Rev-Erb B and N-CoR (B) were measured 
by real-time PCR. The mean values and the standard devia-
tions of two different series are shown. A decrease of full-
length AFP-RNA (AFP1; – 4.5 fold) and the smaller splicing 
products (AFP2; -4.5 fold) could be seen after 12 hours; 
afterwards, a continuous increase could be observed of both 
products with a maximum after 72 hours (AFP1 up to 7.0 
fold and AFP2 up to 4.8 fold). A continuous down regulation 
of Rev-Erb A with the maximum at 48 hours could be 
observed, 24 hour later both AFP products were maximally 
up regulated. Rev-Erb and N-CoR show only slight changes in 
this model.
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was performed with liver RNA samples of 2-AAF treated
rats, after PH or after sham operation. A positive hybridi-
zation signal of about 2.1 kb was observed only in liver
samples from 2-AAF treated rats after PH; but not after
sham operation (Figure 2). In order to support our
assumption, the two primer pairs were also tested in fetal
rat liver. In the fetal liver the full-length AFP-RNA is highly
expressed. In real-time PCR analysis, a strongly increased
expression of full-length AFP-RNA (AFP1) with a maxi-
mum at day 14 (21,500 fold) could be shown. Only a
weak expression (582 fold) of the smaller AFP-RNA vari-
ants (AFP2) at the same time points was seen (Figure 6).
Fetal AFP was not detected in the liver of animals after
normal PH. In this vein, we concluded that primer AFP1
detects the full-length AFP-RNA and the primer AFP2
detects the truncated AFP. The full-length AFP-RNA is
translated into a 68 kDa and 70 kDa protein. The AFP
antibody we used for the Western blot analysis detected
the 68 kDa and 70 kDa protein in fetal liver; a strong sig-
nal could be seen at those sizes. But in case of rats treated
with 2-AAF and PH, only weak signals could be detected
by 68 kDa and 70 kDa at the different time points; further-
more, smaller protein products could be not seen, how-
ever, no strong changes could be observed on protein
level. The possible explanation for these findings is that
the amount of the full-length AFP-RNA protein is very low
in comparison with that contained in the fetal liver, there-
fore, no changes could be detected in those samples. The
difference between fetal AFP gene expression in the fetal
liver (maximum at day 14: 21,500 fold) and in the liver of
2-AAF treated animals after PH (maximum at day 7: 400
fold) was about 54 fold.
Western blot analysis of AFP expression in the rat liver Figure 8
Western blot analysis of AFP expression in the rat 
liver. The fetal AFP-RNA is translated into a 68 kDa and 70 
kDa protein. The smaller AFP-RNA transcripts are translated 
into smaller protein products (58 kDa, 54 kDa and 44 kDa). 
The strongest expression of fetal AFP protein could be 
detected in the fetal liver. After PH and 2-AAF treatment, a 
clearly weaker expression of proteins with a size of 68 kDa 
and 70 kDa could be seen; but no smaller protein products 
could be observed. In the case of the normal PH and of the 
normal control (no co), beside a weak 68 kDa signal also a 
smaller protein product could be detected.
Expression of AFP gene and Rev-Erb A, Rev-Erb B and N- CoR during acute phase reaction Figure 7
Expression of AFP gene and Rev-Erb A, Rev-Erb B 
and N-CoR during acute phase reaction. After turpen-
tine oil treatment, the expression of AFP gene (A) and of 
Rev-Erb A, Rev-Erb B and N-CoR (B) were measured by 
real-time PCR in the rat liver. The mean values of the two 
different series are demonstrated in this Figure. In this 
model, only a slight up regulation of the AFP gene expression 
could be observed at 48 h. The strongest down regulation of 
Rev-Erb A occurs at 2, 24 and 36 hours. Compared to Rev-
Erb A, Rev-Erb B gene expression was not significantly 
altered, e.g., decreased maximally by 4.5 fold at 24 hours.
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In the CCl4 rat model of acute liver damage an increase of
full-length AFP-RNA (AFP1) up to 7 fold, and of the
smaller splicing variants (AFP2) up to 5 fold could be
observed after 72 h hours. Our results are similar to those
of Lemire et al . [11]; in fact, they described also the max-
imum increase of the full-length AFP-RNA after 72 hours
and of the smaller transcripts up to 4 fold at the same time
point.
In the model of normal liver regeneration (PH without 2-
AAF treatment), the full-lenght AFP-RNA transcript
(AFP1) is slightly down regulated at each time point, no
really strong changes could be detected. But in case of the
smaller AFP-RNA transcripts (AFP2), a continuous down
regulation from 2 hours (- 4.7 fold) up to 16 hours (-25.7
fold) could be seen. Compared to 16 hours, an increase of
the smaller splicing products up to -5.1 fold could be
observed after 24 hours; then, the level of do not change
up to 72 hours. The slight changes in the case of full-
length AFP-RNA and the stronger chances in case of the
smaller variants of AFP-RNA, as described above, support
the theory that, in the adult liver, normally only the
smaller variants were expressed and no regeneration takes
place via oval cells. No induction of the full-length AFP-
RNA or the smaller AFP-RNA transcript could be observed
after induction of an acute phase reaction by turpentine
oil in our control model.
So far, the exact regulation of AFP is still unknown; there-
fore, another aim of our study was to analyse the expres-
sion of the orphan nuclear receptors genes (Rev-Erb A,
Rev-Erb B and N-CoR) suggested to control the expression
of AFP negatively. Transfection experiments performed on
human Hep G2 hepatoma cells showed that overproduc-
tion of ROR-α stimulated the activity of AFP enhancers in
a dose-dependent manner, whereas that of Rev-Erb A and
Rev-Erb B had the opposite effect. It was suggested that the
activities of those orphan receptors in cells of hepatic or
endodermal origin could modulate AFP gene expression,
in response to a variety of developmental or carcinogenic
stimuli [16]. In our study, the expression of the orphan
receptors Rev-Erb A, Rev-Erb B and N-CoR was investi-
gated,  in vivo, and in different animal models of liver
regeneration, liver injury, acute phase reaction and in the
fetal liver. In these models, a down regulation of the
orphan receptors (Rev-Erb A, Rev-Erb B and N-CoR) could
be seen, at nearly all time points. The expression of the
full-length AFP-RNA was up regulated after PH in 2-AAF
treated rats (maximum at day 7: 400 fold) (Figure 3) and
after acute liver damage (CCl4 treatment; maximum after
72 hours: 7 fold) (Figure 5) at the same time points Rev-
Erb A and Rev-Erb B were always down regulated. That
means that at those time points no inhibitory effect of
Rev-Erb A and Rev-Erb B of the AFP gene expression takes
place. However, no AFP up regulation was observed in the
other models when the genes of the orphan nuclear recep-
tors were also down regulated. But the reason why the
orphan nuclear receptors were down regulated at nearly
all time points still remains unclear. Possible explanations
for those findings are, on the one hand, that the regula-
tion of the AFP gene and the orphan nuclear receptors dif-
fers in different organisms and, on the other hand, that in
vivo some other additional factors may participate in the
regulation of the AFP gene expression and of the orphan
nuclear receptors. Because no rat specific antibodies
against Rev-Erb A and Rev-Erb B were commercially avail-
able, an attempt to verify the results of the Real-time PCR
at protein level could be not performed. Therefore, and as
an alternative, we tried Western blot analysis and immu-
nohistological staining with human antibodies; but no
specific signal could be detected. Possible explanations for
these findings are: (1) the antibodies do not react with the
rat samples or (2) the protein level is too low. For address-
ing to the second point, we studied the relationship
between full-length (fetal AFP) and adult (smaller vari-
ants) AFP on RNA level and, then, on protein level. The
difference between expression of the full-length AFP-RNA
in the fetal rat liver (maximum at day 14: 21,500 fold) and
after PH in 2-AAF treated rats (maximum at day 7: 400
fold) was about 54 fold. On protein level, studied by
Western blot analysis, we could reproduce these results. In
comparison to the fetal liver, with a strong specific signal,
the full-length AFP protein was only barely detectable in
the total liver proteins of the rat livers after PH with after
2-AAF treatment. Therefore, it is understandable that the
detection of transcription factors like the orphan nuclear
receptors became even more difficult, because they are
normally low expressed and in this study additional still
down regulated.
Conclusion
The proliferation of oval cells could be demonstrated in 2-
AAF treated rats after PH, on RNA level by real-time PCR
with a specific primer pair (AFP1) and on protein level by
immunostaining. Only traces of the oval cell specific AFP
transcripts could be observed in regenerating livers with-
out 2-AAF treatment. The orphan receptor genes, which
could influence the AFP gene expression in vitro, showed
in the oval cell model (PH with 2-AAF treatment) and, in
the model of acute liver damage, a down regulation of Rev
Erb A and Rev Erb B at the same time points of the up reg-
ulation of the AFP gene expression. Yet, down regulation
of the orphan nuclear receptor genes could also be
observed nearly at all time points in the different model;
therefore, the correlation of AFP gene and orphan nuclear
receptors is not really clear. Further investigations will be
necessary for understanding the regulation of AFP gene in
rodent models of oval cell proliferation and in human
hepatocellular carcinomas. Eventually, novel regulatoryComparative Hepatology 2006, 5:2 http://www.comparative-hepatology.com/content/5/1/2
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factors of AFP gene expression could be utilized as early
markers of hepatocarcinogenesis.
Materials and methods
Animals
Male Wistar rats (180–200 g) were provided by Winkel-
mann (Borchen, Germany) and used for animal models
of acute liver injury or acute phase response and further
used for studying liver regeneration after PH. Two series
were performed for each model. The animals were kept
with food and water, ad libitum. For each model of liver
regeneration and liver injury, two different series were per-
formed. The animals were kept according to our institu-
tion's and the National Institutes of Health guidelines.
Different rat models of liver regeneration
Proliferation of hepatic progenitor cells (oval cells) was
studied in rats treated with 2-AAF, after PH. Rats received
1.5 mg 2-AAF daily by intragastric gavage and PH or sham
operation was perfomed on the sixth day. On the day of
surgery and on the first postoperative day, 2-AAF was not
given. PH was performed under ether anaesthesia by mid-
ventral laparotomy with 70% liver resection. A control
animal was subjected to sham operation by the same
operator. Under similar conditions, sham operations con-
sisted of a midventral laparotomy, gentle manipulation of
the liver and surgical closure of the abdomen. Treatment
with 2-AAF was restarted on the second postoperative day
and continued for another 5 days to a total dose of 15 mg
per rat. Rats were sacrificed on the day of surgery (con-
trol), day 1 after PH or sham, and days 3, 7, 11 and 13
(each PH and sham operation). Normal liver regeneration
without 2-AAF treatment was studied after standard PH or
sham operation. Rats were sacrificed on the day of surgery
(control), and 2, 4, 8, 16, 24, 48 and 72 hours, after PH or
sham operation. Livers were snap-frozen in liquid nitro-
gen and stored at -80°C.
Rat model of acute liver damage
Acute liver damage was induced in 8 weeks old Wistar rats
by oral administration of a CCl4/maize oil solution (50%
v/v) according to Yokoi [40], as previously described [41].
For studying the time kinetics, rats were sacrificed 6, 12,
24, 48, 72 and 96 hours, after a single CCl4 administra-
tion. Livers were snap-frozen in liquid nitrogen and stored
at -80°C.
Rat model of acute phase reaction
Acute phase reaction was induced in male Wistar rats by
injection of 2.5 ml/kg turpentine oil into the right and left
hind limp, intramusculary, as reported [42]; control ani-
mals received no injections. Liver tissue was removed after
30 minutes, and 1, 2, 4, 6, 12, 24, 36 and 48 hours, after
injection. Livers were snap-frozen in liquid nitrogen and
stored at -80°C.
Immunohistology
Rat liver cryostat sections were fixed in methanol/acetone,
at -20°C. After inactivation of endogeneous peroxidases
with 0.01 M glucose, 250 U glucose oxidase and 1 mM
sodium azide in phosphate-buffered saline (PBS), sec-
tions were incubated with fetal calf serum, for 30 minutes
at room temperature. The sections were incubated with a
rabbit antiserum against human AFP (DAKO, Glostrup,
Denmark) diluted 1:50 in PBS, at 4°C overnight. After
washing in PBS, sections were incubated with a peroxi-
dase-conjugated secondary antibody (Swine anti-Rabbit,
DAKO, Glostrup, Denmark), for 60 minutes at room tem-
perature. As a substrate for immunostaining, 3,3'-diami-
nobenzidine tetrahydrochloride was used.
Western blot analysis
Lysates were prepared by homogenization of tissue at 4°C
in 20 mM Tris-HCl (pH 8.0), 5 mM EDTA, 3 mM EGTA, 1
mM DTT, 1% SDS, 1 mM PMSF, and protease inhibitor
cocktail (Sigma-Aldrich Inc.). Samples were cleared by
centrifugation at 15,000 g for 15 min at 4°C, and the pro-
tein concentration was measured by BCA assay (Pierce,
Rockford, IL, USA), using bovine serum albumin, as
standard. Protein lysates were separated on SDS-polyacry-
lamide gels, electrotransferred to polyvinylidene difluo-
ride membranes (Invitrogen, USA), probed with primary
antibodies overnight. The appropriate peroxidase-conju-
gated secondary antibodies (DAKO, Glostrup, Denmark)
in a dilution of 1:5,000 were then added and incubation
continued for 1 hour, at room temperature. Bound anti-
bodies were visualized using chemiluminescent substrate
(ECL; Amersham-Pharmacia, UK). Equal loading was pre-
viously controlled by transient Ponceau S staining. The
primary antibodies included: human anti-AFP (DAKO,
Glostrup, Denmark), human anti-RevErbα/NR1D1 (R&D
Systems, Wiesbaden, Germany) and human anti-
RevErbβ/NR1D2 (R&D Systems, Wiesbaden, Germany).
Probes were also extracted from rat hepatoblasts and
hepatoma cells (Hep G2, Hep 3B).
Isolation of total RNA
Frozen liver samples were lysed in 3 ml guanidinium iso-
thiocyanate buffer [43], as described elsewhere [44]. Sub-
sequently, total cellular RNA was isolated by cesium
chloride density gradient centrifugation [45] and the RNA
concentration was determined photometrically.
Northern blot analysis
Total RNA was resolved by agarose gel electrophoresis,
transferred on nylon membranes and hybridized with
cDNA probe specific for the full-length AFP mRNA (AFP1
fragment). The cDNA probe was 32P-labed by nick trans-
lation or by random priming. Hybridiziation was per-
formed under high-stringency conditions for 2 hours, at
68°C, using the QuickHyB® (Stratagene, La Jolla, Califor-Comparative Hepatology 2006, 5:2 http://www.comparative-hepatology.com/content/5/1/2
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nia). Posthybridization washes were performed 2 times
for 15 minutes each at room temperature, and 1 time for
5 to 15 minutes at 60°C in two fold standard sodium cit-
rate containing 0.1% sodium dodecyl sulfate (SDS).
Nylon filters exposed to Kodak X-omat x-ray films, at -
80°C.
Quantification of gene expression by real-time PCR
The reverse transcriptase reaction was carried out in 0.1 M
Tris chloride (pH 8.3), 10 mM magnesium chloride, 10
mM dithiothreitol using 1 mM of each deoxynucleotide
(dATP, dCTP, dGTP, dTTP, Boehringer Mannheim, Ger-
many), 200 units of Moloney murine leukaemia virus
reverse transcriptase (M-MLV-RT, Invitrogene, Karlsruhe,
Germany), and 16 units of RNasin in a total volume of 20
μl for 1 hour at 40°C using 1 μg denatured total RNA and
Oligo (dT)15 primer.
The expression of mRNAs was measured by real-time PCR,
a method to precisely quantify mRNA. The cDNA was
amplified with a set of gene-specific primers and SYBR
Green Master Mix (Applied Biosystems, Foster City, Cali-
fornia), according to the manufacturer's protocol, in a
PRISM 7000 Sequence Detection system (Applied Biosys-
tems, Foster City, California). Primers used in the real-
time PCR experiments are summarized in Table 1. Ampli-
fied PCR products were monitored by measuring the
increase in fluorescence caused by the binding of SYBR
Green dye to double-stranded DNA. Real-time PCR was
performed twice for each sample. The amount of compar-
ative expression level of the target, normalized to an
endogenous reference (β-actin) and relative to a calibrator
(control animal at time point 0 h), is given by 2-ΔΔC 
T.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
VM was responsible for the primer design, carried out the
Northern blot analysis and real-time PCR analysis, and
drafted the manuscript. KT carried out experiments with
the rat models for acute liver damage (treatment with
CCl4) and for acute phase reaction (treatment with tur-
pentine oil). DB carried out the experiments with rat mod-
els for liver regeneration (PH with and without 2-AAF
treatment) and the immunostaining with an antibody
against AFP. AE performed the experiments with the fetal
rat liver. GR conceived this study, and participated in the
design and coordination of the different experiments and
helped to draft the manuscript.
Acknowledgements
The authors are indebted to Mrs. Melanie Heinemann and Mrs. Christin 
Hoffmann for excellent technical assistance.  This work was supported by 
grants of the Deutsche  Forschungsgemeinschaft(DFG) SFB 402, Teilpro-
jekte C6, D3, D4.
References
1. Evarts RP, Nagy P, Marsden E, Thorgeirsson SS: A precursor-prod-
uct relationship exists between oval cells and hepatocytes in
rat liver.  Carcinogenesis 1987, 8(11):1737-1740.
2. Kuhlmann WD: Localization of alpha1-fetoprotein and DNA-
synthesis in liver cell populations during experimental hepa-
tocarcinogenesis in rats.  Int J Cancer 1978, 21(3):368-380.
3. Sell S, Dunsford HA: Evidence for the stem cell origin of hepa-
tocellular carcinoma and cholangiocarcinoma.  Am J Pathol
1989, 134(6):1347-1363.
4. Bernier D, Thomassin H, Allard D, Guertin M, Hamel D, Blaquiere M,
Beauchemin M, LaRue H, Estable-Puig M, Belanger L: Functional
analysis of developmentally regulated chromatin-hypersen-
sitive domains carrying the alpha 1-fetoprotein gene pro-
moter and the albumin/alpha 1-fetoprotein intergenic
enhancer.  Mol Cell Biol 1993, 13(3):1619-1633.
5. Nahon JL: The regulation of albumin and alpha-fetoprotein
gene expression in mammals.  Biochimie 1987, 69(5):445-459.
6. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T: Clinical
significance of elevated alpha-fetoprotein (AFP) in patients
with chronic hepatitis C, but not hepatocellular carcinoma.
Am J Gastroenterol 2004, 99(5):860-865.
7. Bayati N, Silverman AL, Gordon SC: Serum alpha-fetoprotein
levels and liver histology in patients with chronic hepatitis C.
Am J Gastroenterol 1998, 93(12):2452-2456.
8. Johnson PJ: Role of alpha-fetoprotein in the diagnosis and
management of hepatocellular carcinoma.  J Gastroenterol
Hepatol 1999, 14 Suppl:S32-6.
9. Tong MJ, Blatt LM, Kao VW: Surveillance for hepatocellular car-
cinoma in patients with chronic viral hepatitis in the United
States of America.  J Gastroenterol Hepatol 2001, 16(5):553-559.
10. Hellerbrand C, Hartmann A, Richter G, Knoll A, Wiest R, Scholm-
erich J, Lock G: Hepatocellular carcinoma in southern Ger-
many: epidemiological and clinicopathological
characteristics and risk factors.  Dig Dis 2001, 19(4):345-351.
11. Lemire JM, Fausto N: Multiple alpha-fetoprotein RNAs in adult
rat liver: cell type-specific expression and differential regula-
tion.  Cancer Res 1991, 51(17):4656-4664.
12. Bisgaard HC, Nagy P, Ton PT, Hu Z, Thorgeirsson SS: Modulation
of keratin 14 and alpha-fetoprotein expression during
hepatic oval cell proliferation and liver regeneration.  J Cell
Physiol 1994, 159(3):475-484.
13. Poliard A, Bakkali L, Poiret M, Foiret D, Danan JL: Regulation of the
rat alpha-fetoprotein gene expression in liver. Both the pro-
moter region and an enhancer element are liver-specific and
negatively modulated by dexamethasone.  J Biol Chem 1990,
265(4):2137-2141.
14. Spear BT: Mouse alpha-fetoprotein gene 5' regulatory ele-
ments are required for postnatal regulation by raf and Rif.
Mol Cell Biol 1994, 14(10):6497-6505.
15. Jin DK, Vacher J, Feuerman MH: alpha-Fetoprotein gene
sequences mediating Afr2 regulation during liver regenera-
tion.  Proc Natl Acad Sci U S A 1998, 95(15):8767-8772.
16. Bois-Joyeux B, Chauvet C, Nacer-Cherif H, Bergeret W, Mazure N,
Giguere V, Laudet V, Danan JL: Modulation of the far-upstream
enhancer of the rat alpha-fetoprotein gene by members of
the ROR alpha, Rev-erb alpha, and Rev-erb beta groups of
monomeric orphan nuclear receptors.  DNA Cell Biol 2000,
19(10):589-599.
17. Giguere V, Tini M, Flock G, Ong E, Evans RM, Otulakowski G: Iso-
form-specific amino-terminal domains dictate DNA-binding
properties of ROR alpha, a novel family of orphan hormone
nuclear receptors.  Genes Dev 1994, 8(5):538-553.
18. Retnakaran R, Flock G, Giguere V: Identification of RVR, a novel
orphan nuclear receptor that acts as a negative transcrip-
tional regulator.  Mol Endocrinol 1994, 8(9):1234-1244.
19. Bonnelye E, Vanacker JM, Desbiens X, Begue A, Stehelin D, Laudet V:
Rev-erb beta, a new member of the nuclear receptor super-
family, is expressed in the nervous system during chicken
development.  Cell Growth Differ 1994, 5(12):1357-1365.
20. Forman BM, Chen J, Blumberg B, Kliewer SA, Henshaw R, Ong ES,
Evans RM: Cross-talk among ROR alpha 1 and the Rev-erbPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Comparative Hepatology 2006, 5:2 http://www.comparative-hepatology.com/content/5/1/2
Page 12 of 12
(page number not for citation purposes)
family of orphan nuclear receptors.  Mol Endocrinol 1994,
8(9):1253-1261.
21. Adelmant G, Begue A, Stehelin D, Laudet V: A functional Rev-erb
alpha responsive element located in the human Rev-erb
alpha promoter mediates a repressing activity.  Proc Natl Acad
Sci U S A 1996, 93(8):3553-3558.
22. Atkins GB, Hu X, Guenther MG, Rachez C, Freedman LP, Lazar MA:
Coactivators for the orphan nuclear receptor RORalpha.  Mol
Endocrinol 1999, 13(9):1550-1557.
23. Burke LJ, Downes M, Laudet V, Muscat GE: Identification and
characterization of a novel corepressor interaction region in
RVR and Rev-erbA alpha.  Mol Endocrinol 1998, 12(2):248-262.
24. Koibuchi N, Liu Y, Fukuda H, Takeshita A, Yen PM, Chin WW: ROR
alpha augments thyroid hormone receptor-mediated tran-
scriptional activation.  Endocrinology 1999, 140(3):1356-1364.
25. Bergstrand CG, Czar B: Demonstration of a new protein frac-
tion in serum from the human fetus.  Scand J Clin Lab Invest 1956,
8(2):174.
26. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y,
Nagataki S: Early recognition of hepatocellular  carcinoma
based on altered profiles of alpha-fetoprotein.  N Engl J Med
1993, 328(25):1802-1806.
27. Eleftheriou N, Heathcote J, Thomas HC, Sherlock S: Serum alpha-
fetoprotein levels in patients with acute and chronic liver dis-
ease. Relation to hepatocellular regeneration and develop-
ment of primary liver cell carcinoma.  J Clin Pathol 1977,
30(8):704-708.
28. Alpert E, Feller ER: Alpha-fetoprotein (AFP) in benign liver dis-
ease. Evidence that normal liver regeneration does not
induce AFP synthesis.  Gastroenterology 1978, 74(5 Pt 1):856-858.
29. Demetris AJ, Seaberg EC, Wennerberg A, Ionellie J, Michalopoulos G:
Ductular reaction after submassive necrosis in humans. Spe-
cial emphasis on analysis of ductular hepatocytes.  Am J Pathol
1996, 149(2):439-448.
30. Fiel MI, Antonio LB, Nalesnik MA, Thung SN, Gerber MA: Charac-
terization of ductular hepatocytes in primary liver allograft
failure.  Mod Pathol 1997, 10(4):348-353.
31. Haque S, Haruna Y, Saito K, Nalesnik MA, Atillasoy E, Thung SN, Ger-
ber MA: Identification of bipotential progenitor cells in
human liver regeneration.  Lab Invest 1996, 75(5):699-705.
32. Fujikawa T, Hirose T, Fujii H, Oe S, Yasuchika K, Azuma H, Yamaoka
Y: Purification of adult hepatic progenitor cells using green
fluorescent protein (GFP)-transgenic mice and fluores-
cence-activated cell sorting.  J Hepatol 2003, 39(2):162-170.
33. Lowes KN, Croager EJ, Olynyk JK, Abraham LJ, Yeoh GC: Oval cell-
mediated liver regeneration: Role of cytokines and growth
factors.  J Gastroenterol Hepatol 2003, 18(1):4-12.
34. Alison MR, Poulsom R, Forbes SJ: Update on hepatic stem cells.
Liver 2001, 21(6):367-373.
35. Tatematsu M, Kaku T, Medline A, Farber E: Intestinal metaplasia
as a common option of oval cells in relation to cholangiofi-
brosis in liver of rats exposed to 2-acetylaminofluorene.  Lab
Invest 1985, 52(4):354-362.
36. Batusic DS, Cimica V, Chen Y, Tron K, Hollemann T, Pieler T, Rama-
dori G: Identification of genes specific to "oval cells" in the rat
2-acetylaminofluorene/partial hepatectomy model.  Histo-
chem Cell Biol 2005, 124(3-4):245-260.
37. Matsusaka S, Tsujimura T, Toyosaka A, Nakasho K, Sugihara A,
Okamoto E, Uematsu K, Terada N: Role of c-kit receptor tyro-
sine kinase in development of oval cells in the rat 2-
acetylaminofluorene/partial hepatectomy model.  Hepatology
1999, 29(3):670-676.
38. Crosby HA, Kelly DA, Strain AJ: Human hepatic stem-like cells
isolated using c-kit or CD34 can differentiate into biliary epi-
thelium.  Gastroenterology 2001, 120(2):534-544.
39. Yin L, Lynch D, Ilic Z, Sell S: Proliferation and differentiation of
ductular progenitor cells and littoral cells during the regen-
eration of the rat liver to CCl4/2-AAF injury.  Histol Histopathol
2002, 17(1):65-81.
40. Yokoi Y, Namihisa T, Kuroda H, Komatsu I, Miyazaki A, Watanabe S,
Usui K: Immunocytochemical detection of desmin in fat-stor-
ing cells (Ito cells).  Hepatology 1984, 4(4):709-714.
41. Neubauer K, Knittel T, Armbrust T, Ramadori G: Accumulation
and cellular localization of fibrinogen/fibrin during short-
term and long-term rat liver injury.  Gastroenterology 1995,
108(4):1124-1135.
42. Knittel T, Fellmer P, Neubauer K, Kawakami M, Grundmann A, Ram-
adori G: The complement-activating protease P100 is
expressed by hepatocytes and is induced by IL-6 in vitro and
during the acute phase reaction in vivo.  Lab Invest 1997,
77(3):221-230.
43. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of
biologically active ribonucleic acid from sources enriched in
ribonuclease.  Biochemistry 1979, 18(24):5294-5299.
44. Ramadori G, Sipe JD, Colten HR: Expression and regulation of
the murine serum amyloid A (SAA) gene in extrahepatic
sites.  J Immunol 1985, 135(6):3645-3647.
45. Glisin V, Crkvenjakov R, Byus C: Ribonucleic acid isolated by
cesium chloride centrifugation.  Biochemistry 1974,
13(12):2633-2637.